• Publications
  • Influence
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
TLDR
Targeted therapy with this CD30-directed antibody-drug conjugate brentuximab vedotin may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy. Expand
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
TLDR
Mechanistic investigations showed that IFNγ produced by CD8(+) T cells was responsible for mediating PD-L1 upregulation on tumor cells after delivery of fractionated radiotherapy, revealing the mechanistic basis for an adaptive response by tumor cells that mediates resistance to fractionation radiotherapy and its treatment failure. Expand
Consensus guidelines for the detection of immunogenic cell death
TLDR
Strategies conceived to detect surrogate markers of ICD in vitro and to screen large chemical libraries for putative I CD inducers are outlined, based on a high-content, high-throughput platform that was recently developed. Expand
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
TLDR
Patients with early-stage Hodgkin's lymphoma and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation radiotherapy, and the noninferiority of the strategy of no further treatment after chemotherapy with regard to progression-free survival did not show. Expand
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
TLDR
Although the addition of MGd to WBRT did not produce a significant overall improvement between treatment arms, MGd may improve memory and executive function and prolong time to neurocognitive and neurologic progression in patients with brain metastases from lung cancer. Expand
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.
TLDR
In a large, randomised trial, there was no loss of efficacy associated with radiotherapy doses of 24Gy in indolent NHL and 30Gy in aggressive NHL, compared with previous standard doses of 40-45Gy. Expand
Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
TLDR
A new concept, involved site radiation therapy (ISRT), is introduced as the standard conformal therapy for the scenario, commonly encountered, wherein optimal imaging is not available, and it is more conservative than INRT, accounting for suboptimal information and appropriately designed for safe local disease control. Expand
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.
TLDR
Preclinical data points heavily toward a strong synergy between radiotherapy and immune treatments, however, several issues concerning dosage, timing, patient selection and toxicity need to be resolved before the abscopal effect can become clinically relevant. Expand
Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.
TLDR
Newer treatment techniques, including intensity modulated RT, breath holding, image guided RT, and 4-dimensional imaging, should be implemented, and their use is expected to decrease significantly the risk for normal tissue damage while still achieving the primary goal of local tumor control. Expand
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
TLDR
Significant improvement in objective response lasting at least 4 months was seen with brentuximab vedotin versus physician's choice of methotrexate or bexarotene in previously treated patients with CD30-positive cutaneous T-cell lymphomas. Expand
...
1
2
3
4
5
...